Literature DB >> 27626319

Successful application of endoscopic ultrasound-guided fine needle biopsy to establish pancreatic patient-derived tumor xenografts: a pilot study.

Els Hermans1, Schalk W Van der Merwe2, Jeroen Depreeuw1, Jeroen Dekervel2, Enrico Radaelli3, Tania Roskams4, Jos van Pelt Jos2, Baki Topal5, Chris Verslype2, Hans Prenen2, Werner Van Steenbergen2, Frederik Nevens2, Diether Lambrechts6, Frédéric Amant1.   

Abstract

Background and study aim: Typically, pancreatic patient-derived tumor xenografts (PDXs) are established by transplanting large tumor biopsies obtained through invasive surgery approaches into immunocompromised mice. We aimed to develop pancreatic PDXs by transplanting tumor tissue acquired by endoscopic ultrasound (EUS)-guided fine needle biopsies (FNB), assess take rates compared to surgery-derived PDXs, and demonstrate the histological and genetic resemblance to the original tumor. Patients and methods: Biopsies of untreated pancreatic carcinoma were collected at surgery and during EUS and processed to generate PDXs.
Results: By centrifugation of FNB-derived tissue prior to engraftment, we achieved an engraftment rate of 60 % (6/10). Despite a decrease in stromal tissue, the general morphology of FNB-derived PDXs was conserved as assessed by histopathology. At the genetic level, somatic mutation and copy number profiles were largely similar to the primary tumor.
Conclusion: We show that it is technically feasible to establish pancreatic PDXs using a minimally invasive sampling technique, such as EUS-FNB. Although only a limited amount of tumor tissue was acquired, we obtained results similar to those from surgery-derived PDXs. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27626319     DOI: 10.1055/s-0042-113597

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  5 in total

Review 1.  The Impact of Recent Advances in Endoscopic Ultrasound-Guided Tissue Acquisition on the Management of Pancreatic Cancer.

Authors:  Susana Marques; Miguel Bispo; Ricardo Rio-Tinto; Paulo Fidalgo; Jacques Devière
Journal:  GE Port J Gastroenterol       Date:  2020-10-23

2.  Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer Xenografts.

Authors:  Ashenafi Bulle; Jeroen Dekervel; Lise Deschuttere; David Nittner; Eric Van Cutsem; Chris Verslype; Jos van Pelt
Journal:  Onco Targets Ther       Date:  2020-07-15       Impact factor: 4.147

Review 3.  Advanced EUS Guided Tissue Acquisition Methods for Pancreatic Cancer.

Authors:  Pujan Kandel; Michael B Wallace
Journal:  Cancers (Basel)       Date:  2018-02-17       Impact factor: 6.639

4.  Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer.

Authors:  Ashenafi Bulle; Jeroen Dekervel; Lise Deschuttere; David Nittner; Louis Libbrecht; Rekin's Janky; Stéphane Plaisance; Baki Topal; An Coosemans; Diether Lambrechts; Eric Van Cutsem; Chris Verslype; Jos van Pelt
Journal:  Transl Oncol       Date:  2020-03-04       Impact factor: 4.243

5.  Establishment and characterization of patient-derived head and neck cancer models from surgical specimens and endoscopic biopsies.

Authors:  Daniel Strüder; Theresa Momper; Nina Irmscher; Mareike Krause; Jan Liese; Sebastian Schraven; Annette Zimpfer; Sarah Zonnur; Ann-Sophie Burmeister; Björn Schneider; Bernhard Frerich; Robert Mlynski; Christina Große-Thie; Christian Junghanss; Claudia Maletzki
Journal:  J Exp Clin Cancer Res       Date:  2021-08-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.